CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML

Travaglini, Serena; Ottone, Tiziana; Angelini, Daniela F.; Fiori, Valentina; Dominici, Sabrina; Noguera, Nélida I.; Śniegocka, Martyna; Antonelli, Silvia; Consalvo, María Antonietta Irno; Bardi, Marco De; Banella, Cristina; Divona, Mariadomenica; Marchesi, Francesco; Masciarelli, Silvia; Fazi, Francesco; Pieraccioli, Marco; Palmieri, Raffaele; Angelis, Gottardo De; Buccisano, Francesco; Venditti, Adriano; Battistini, Luca; Magnani, Mauro; Voso, Maria Teresa

doi:10.1038/s41375-022-01566-5

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute myeloid leukemia (AML), they induce cell death and inhibit xenografts without the involvement of immune effector cells, via SRC family kinase activation [39]. Notably, AML with FLT3 internal tandem duplication mutations displays strong apoptotic activity from anti-CD99 antibodies, involving the intrinsic and extrinsic apoptotic pathways [29]. Additionally, these antibodies prove effective in mantle B-cell lymphoma [40].…”

Section: Discussionmentioning

confidence: 99%

“…The relative qRT-PCR for CD99wt and CD99sh quantitation was performed on Applied Biosystems 7500 apparatus (Thermo Fisher Scientific, Waltham, MA, USA) using primers and probe elsewhere described [29]: 2 isoform-specific CD99 reverse primer for the CD99 wild-type (CD99_ wild-type: 5 ′ -ATGTCCACCTCCCCTTGTT-3 ′ ) and short (CD99_Sh: 5 ′ -TGCTCACCCCTAGGTCTT-3 ′ ) isoforms, and a common forward primer (CD99 Fw: 5 ′ -CTGGAGCCATCTCTAGCTT-3 ′ ) and probe (5 ′ -(FAM)TTCTTTTTCTGGTAAGCA-3 ′ ). GAPDH was used as reference gene for normalization and was amplified in a multiplex reaction with CD99 using primers and probe described in [30]: GAPDH Up: 5 ′ -ATGGGTGTGAACCATGAGAA-3 ′ , GAPDH Low: 5 ′ -GTGCTAAGCAGTTGGTGGTG-3 ′ , and the probe 5 ′ -(VIC) CCTCAAGATCATCAGCAATGCCTCC-3 ′ .…”

Section: Quantitative Real-time Pcrmentioning

confidence: 99%

See 1 more Smart Citation

CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study

Rocca,

Giudici,

Donofrio

et al. 2024

Cells

Self Cite

View full text Add to dashboard Cite

Glioblastoma is the most frequent and aggressive brain tumor in adults. This study aims to evaluate the expression and prognostic impact of CD99, a membrane glycoprotein involved in cellular migration and invasion. In a cohort of patients with glioblastoma treated with surgery, radiotherapy and temozolomide, we retrospectively analyzed tumor expression of CD99 by immunohistochemistry (IHC) and by quantitative real-time polymerase chain reaction (qRT-PCR) for both the wild type (CD99wt) and the truncated (CD99sh) isoforms. The impact on overall survival (OS) was assessed with the Kaplan–Meier method and log-rank test and by multivariable Cox regression. Forty-six patients with glioblastoma entered this study. Immunohistochemical expression of CD99 was present in 83%. Only the CD99wt isoform was detected by qRT-PCR and was significantly correlated with CD99 expression evaluated by IHC (rho = 0.309, p = 0.037). CD99 expression was not associated with OS, regardless of the assessment methodology used (p = 0.61 for qRT-PCR and p = 0.73 for IHC). In an exploratory analysis of The Cancer Genome Atlas, casuistry of glioblastomas CD99 expression was not associated with OS nor with progression-free survival. This study confirms a high expression of CD99 in glioblastoma but does not show any significant impact on survival. Further preclinical studies are needed to define its role as a therapeutic target in glioblastoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Quantitative Real-time Pcrmentioning

confidence: 99%

CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study

Rocca,

Giudici,

Donofrio

et al. 2024

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…CD99 targeting also reduced glycolysis and mitochondrial respiration. 220 Targeting CD33 with gemtuzumab ozogamicin (GO), a calicheamicin-conjugated mAb, in combination with induction chemotherapy in pediatric patients with high FLT3-ITD AR reduced relapse. 221 An active clinical trial (NCT04385290) is investigating the safety and efficacy of midostaurin plus GO as frontline therapy in newly diagnosed FLT3 mutated patients.…”

Section: Targeted Flt3 Aml Therapeutics Beyond Flt3 Inhibitorsmentioning

confidence: 99%

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

Tecik¹,

Adan²

2022

OTT

View full text Add to dashboard Cite

FMS-like tyrosine kinase 3 (FLT3) is mutated in approximately 30% of acute myeloid leukemia (AML) patients. The presence of FLT3-ITD (internal tandem duplication, 20–25%) mutation and, to a lesser extent, FLT3-TKD (tyrosine kinase domain, 5–10%) mutation is associated with poorer diagnosis and therapy response since the leukemic cells become hyperproliferative and resistant to apoptosis after continuous activation of FLT3 signaling. Targeting FLT3 has been the focus of many pre-clinical and clinical studies. Hence, many small-molecule FLT3 inhibitors (FLT3is) have been developed, some of which are approved such as midostaurin and gilteritinib to be used in different clinical settings, either in combination with chemotherapy or alone. However, many questions regarding the best treatment strategy remain to be answered. On the other hand, various FLT3-dependent and -independent resistance mechanisms could be evolved during FLT3i therapy which limit their clinical impact. Therefore, identifying molecular mechanisms of resistance and developing novel strategies to overcome this obstacle is a current interest in the field. In this review, recent studies of approved FLT3i and knowledge about major resistance mechanisms of clinically approved FLT3i’s will be discussed together with novel treatment approaches such as designing novel FLT3i and dual FLT3i and combination strategies including approved FLT3i plus small-molecule agents targeting altered molecules in the resistant cells to abrogate resistance. Moreover, how to choose an appropriate FLT3i for the patients will be summarized based on what is currently known from available clinical data. In addition, strategies beyond FLT3i’s including immunotherapeutics, small-molecule FLT3 degraders, and flavonoids will be summarized to highlight potential alternatives in FLT3-mutated AML therapy.

show abstract

AML: making residual disease more measurable

Voso

Buccisano

2022

Blood

View full text Add to dashboard Cite

CD99 as a novel therapeutic target on leukemic progenitor cells in FLT3-ITDmut AML

Cited by 3 publications

References 10 publications

CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study

CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort Study

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

AML: making residual disease more measurable

Contact Info

Product

Resources

About